ABT

Abbott (ABT) Reports Strong Q3 2024 Results

Abbott Reports Strong Third-Quarter 2024 Results and Raises Full-Year EPS Guidance

Abbott has reported strong financial results for the third quarter ended September 30, 2024. The company's sales reached $10.6 billion, representing a 4.9% growth compared to the same period last year. Organic sales growth for the underlying base business was even more robust at 8.2%. This growth was driven by double-digit growth in medical devices, which saw a 13.3% increase in sales.

In terms of specific business segments, the nutrition business witnessed a 3.4% increase in sales on an organic basis. The adult nutrition segment led this growth with a 9.1% increase in sales. For diagnostics, excluding the impact of Covid-19 testing-related sales, global sales experienced a 3.3% increase on an organic basis, with core laboratory diagnostics sales growing 4.5%. Established pharmaceuticals sales also saw a 7.0% increase on an organic basis, with key emerging markets contributing to this growth.

The medical devices segment was particularly strong, with worldwide sales increasing by 13.3% on an organic basis. Diabetes care sales, in particular, exceeded $1.6 billion, representing a 20.7% organic growth.

Looking ahead, Abbott has raised the midpoint of its full-year EPS guidance range. The company now projects full-year diluted EPS on a GAAP basis of $3.34 to $3.40 and adjusted diluted EPS of $4.64 to $4.70, representing an increase at the midpoint of the guidance range.

Abbott's Board of Directors also authorized a new share repurchase program of up to $7 billion of the company's common shares, demonstrating confidence in the company's performance and financial position.

The market has reacted to these announcements by moving the company's shares 1.9% to a price of $118.2. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS